Form 8-K

8-K — 60 DEGREES PHARMACEUTICALS, INC.

Accession: 0001213900-26-112698

Filed: 2026-10-27

Period: 2026-10-27

CIK: 0001946563

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0309690-8k_60degrees.htm (Primary)

EX-99.1 — PRESS RELEASE DATED OCTOBER 27, 2026 (ea030969001ex99-1.htm)

GRAPHIC (ea030969001_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0309690-8k_60degrees.htm · Sequence: 1

false

0001946563

2026-10-27

0001946563

SXTP:CommonStockParValue0.0001PerShareMember

2026-10-27

0001946563

SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember

2026-10-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM 8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d)

THE SECURITIES EXCHANGE ACT OF 1934

Date

of Report (Date of earliest event reported): October 27, 2026

DEGREES PHARMACEUTICALS, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-41719

45-2406880

(State

or other jurisdiction

of Incorporation)

(Commission

File Number)

(IRS

Employer

Identification Number)

1025

Connecticut Avenue NW Suite 1000,

Washington,

D.C.

20036

(Address

of registrant’s principal executive office)

(Zip

code)

(202) 327-5422

(Registrant’s

telephone number, including area code)

Not

Applicable

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.0001 per share

SXTP

The

Nasdaq Stock Market LLC

Warrants,

each warrant to purchase one share of Common Stock

SXTPW

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01 Other Events.

October 27, 2026, the Company issued a press release announcing its clinical improvement and negative PCR results in all completed expanded

access Babesiosis study patients. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and

incorporated herein by reference.

Item

9.01 Financial Statements and Exhibits

(a)

Exhibits

Number

Description

99.1

Press Release dated October 27, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

DEGREES PHARMACEUTICALS, INC.

Date:

October 27, 2026

By:

/s/

Geoffrey Dow

Name:

Geoffrey

Dow

Title:

Chief

Executive Officer and President

EX-99.1 — PRESS RELEASE DATED OCTOBER 27, 2026

EX-99.1

Filename: ea030969001ex99-1.htm · Sequence: 2

Exhibit

99.1

Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

● All

five completed patients (100%) reported much or very much improved clinical outcomes and

tested negative for Babesia on conventional PCR tests

● Four

of five completed patients (80%) were negative on highly sensitive post-treatment NAT testing

● Results

reinforce favorable retreatment-free outcomes reported with tafenoquine–atovaquone

regimens

● Two

additional patients remain on treatment, bringing total enrollment to seven; study remains

open pending potential discussions with FDA

WASHINGTON,

October 27, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the

“Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced clinical

and molecular results from the first five patients to complete treatment with tafenoquine-containing combination regimens in the

Company’s expanded access study of relapsing babesiosis in immunosuppressed patients (NCT06478641).

All

five patients reported being much improved or very much improved on study-completion forms, and each had negative conventional polymerase

chain reaction (PCR) test results for Babesia documented during treatment or subsequent follow-up. Four of the five patients (80%)

were also nonreactive on a highly sensitive blood-donor nucleic acid amplification test (NAT) for Babesia performed on blood collected

after treatment. The remaining patient had a reactive blood-donor NAT despite a negative follow-up conventional PCR result from Mayo

Clinic.

Human

babesiosis is a tick-borne illness that can cause fever, chills, sweats, joint aches, and fatigue. In immunosuppressed patients, infection

can persist or recur despite treatment and can be life-threatening. Krause and colleagues reported fatal outcomes in three of 14 patients

(21%) with persistent or relapsing babesiosis in their 2008 study. A broader 2025 multicenter study by Kakoullis and colleagues reported

12-month all-cause mortality of 7% among patients who were immunocompromised and/or had impaired splenic function, compared with 1% among

immune-intact patients. Human babesiosis is an orphan disease.

The

Company’s open-label, multi-site expanded access study evaluates the safety and efficacy of tafenoquine combined with atovaquone

and other antimalarial or antibiotic medications in patients with relapsing babesiosis and risk factors for severe disease. The study

builds on findings published in Clinical Infectious Diseases in 2024 by researchers from the Yale School of Public Health, Tufts

Medical Center, Brown University and other institutions.

Current

guidance emphasizes the importance of duration of therapy, recommending at least six consecutive weeks of antibabesial therapy for highly

immunocompromised patients, including two final weeks without parasites detected on blood smears before stopping treatment. Microscopy

can miss low-level parasitemia capable of causing relapse despite clinical improvement, creating a need for more sensitive measures of

parasite clearance. The guidance also allows for more sensitive conventional PCR testing to inform treatment discontinuation on a case-by-case

basis but does not specify PCR-based stopping criteria.

The

expanded access protocol standardizes the treatment discontinuation decision, requiring that tafenoquine, given as part of an

atovaquone combination regimen, be continued until two weeks after two consecutive negative conventional PCR tests and resolution of

babesiosis symptoms. The study then prospectively assesses parasite clearance using a blood-donor NAT assay that is 500-fold more sensitive

than conventional PCR and is not routinely available for patient care. Transfusion-transmitted babesiosis has fallen substantially since

NAT screening of blood donations was introduced. NAT samples from the five completed patients were collected 66–120 days after

completion of tafenoquine treatment.

Current

guidance does not establish a standardized definition of cure for relapsing babesiosis in immunosuppressed patients. However, Krause

and colleagues’ 2008 publication in Clinical Infectious Diseases, on which the prolonged-treatment recommendations are based,

defined cure as the absence of symptoms and parasites detectable on blood smear for more than three months after treatment ended. A 12-week

retreatment-free interval means no additional babesiosis treatment for at least 12 weeks after treatment ends. It provides a practical

indicator of sustained clinical response over a comparable follow-up period.

The

Company has conducted an analysis of published relapsing babesiosis cases and found that six of seven patients (85.7%) treated with tafenoquine–atovaquone

combinations remained retreatment-free for at least 12 weeks after treatment—approximately 3.6 times the model-estimated 23.5%

expected from conventional treatment accounting for the duration of atovaquone coadministration, the accompanying non-tafenoquine

medications and prior treatment history. The association was statistically significant in an exploratory Cox comparison (approximate

patient-clustered score test; two-sided p = 0.019). Together with sequential negative conventional PCR tests in many of these cases,

this finding supports the rationale for the expanded access study: the potential for a higher cure rate when tafenoquine is added

to atovaquone-containing therapy.

the Company’s knowledge, this is the first prospective study in immunosuppressed patients with relapsing babesiosis to combine

a predefined PCR-guided tafenoquine–atovaquone treatment approach with objective post-treatment assessment using a highly

sensitive blood-donor NAT assay. Favorable clinical and conventional-PCR outcomes in all five completed patients and an 80% post-treatment

NAT-negative rate provide molecular evidence consistent with definitive cure in four of five patients. These findings support the Company’s

hypothesis that post-treatment NAT nonreactivity reflects the absence of a biologically relevant circulating parasite burden, marks parasite

eradication and predicts freedom from further babesiosis relapse. The Company reiterates its call for treatment guidance to be updated

to address tafenoquine-containing combinations and sensitive molecular monitoring.

The

Company plans to pursue accelerated approval if the efficacy section of its registration dossier is based primarily on data from immunosuppressed

patients with relapsing babesiosis. In that setting, the Company would propose post-treatment blood-donor NAT nonreactivity as a surrogate

endpoint reasonably likely to predict durable clinical benefit, with a postmarketing confirmatory study designed to verify that benefit

and confirm the relationship between NAT nonreactivity and sustained freedom from relapse.

Two

additional patients remain on treatment in the expanded access study, bringing total enrollment to seven. The study remains open pending

potential discussions with the U.S. Food and Drug Administration (FDA).

The

Company expects to unblind its separate randomized, placebo-controlled study of tafenoquine or placebo added to standard-of-care

therapy in patients hospitalized for babesiosis (NCT06207370) in January 2027. Following unblinding, the Company intends to request a

pre-supplemental New Drug Application (pre-sNDA) meeting with FDA to discuss data from the hospital and expanded access studies and the

appropriate regulatory pathway for tafenoquine in babesiosis.

Tafenoquine

is not FDA-approved for the treatment or prevention of babesiosis. It is approved in the United States for malaria prophylaxis under

the brand name ARAKODA®.

About

ARAKODA (tafenoquine)

Tafenoquine

is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine

for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for

durations of up to six months.

Tafenoquine

was discovered by the Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the

United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed

through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only

malaria prevention drug.

According

to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days,

may offer potential advantages in less frequent dosing for malaria prophylaxis. ARAKODA® is not suitable for everyone, and patients

and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA®

2 x 100 mg tablets once per day for three days prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly

for up to six months during travel, then 2 x 100 mg in the week following travel.

ARAKODA®

(tafenoquine) Important Safety Information

ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older.

Contraindications

ARAKODA should not be administered in the following situations:

● Glucose-6-phosphate

dehydrogenase (“G6PD”) deficiency or unknown G6PD status;

● Breastfeeding

by a lactating woman when the infant is found to be G6PD deficient or if the G6PD status

of the infant is unknown;

● Patients

with a history of psychotic disorders or current psychotic symptoms; or

● Known

hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component

of ARAKODA.

Warnings

and Precautions

Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA due to the risk of hemolytic anemia. Monitor patients

for signs or symptoms of hemolysis.

G6PD

Deficiency in Pregnancy or Lactation: ARAKODA may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus.

ARAKODA is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA through

breast milk. Check the infant’s G6PD status before breastfeeding begins.

Methemoglobinemia:

Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia

occur.

Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia,

at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior)

occur, consider discontinuation of ARAKODA therapy and evaluation by a mental health professional as soon as possible.

Hypersensitivity

Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA. If hypersensitivity reactions occur,

institute appropriate therapy.

Delayed

Adverse Reactions: Due to the long half-life of ARAKODA (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia,

and hypersensitivity reactions may be delayed in onset and/or duration.

Adverse

Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were headache, dizziness, back pain,

diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety.

Drug

Interactions: Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion

transporters.

Use

in Specific Populations: Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during

treatment and for 3 months after the last dose of ARAKODA. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals,

Inc. at 1-888-834-0225 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The full prescribing information of ARAKODA is located here.

About

60 Degrees Pharmaceuticals, Inc.

Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne

disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for

malaria prevention in 2018 and currently has active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA

is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the

U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary

in Australia. Learn more at www.60degreespharma.com.

Cautionary

Note Regarding Forward-Looking Statements

This

press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private

Securities Litigation Reform Act of 1995. Forward-looking statements reflect the current view about future events. When used in this

press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,”

“intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management,

identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead,

they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies,

projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances

that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially

from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important

factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking

statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we

might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain

FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or

other regimen) or castanospermine in a timely manner, we may not be able to expand our business operations; we may not be able to successfully

conduct planned clinical trials; and we have no manufacturing capacity, which puts us at risk of lengthy and costly delays in bringing

our products to market. Findings from a small, uncontrolled expanded access study and historical case comparisons may not predict outcomes

in larger studies. A 12-week retreatment-free interval, clinical improvement and negative conventional PCR results have not been established

as equivalent to post-treatment blood-donor NAT nonreactivity. Post-treatment NAT nonreactivity has not been established as a predictor

of sustained freedom from relapse, and FDA may not accept historical comparisons or post-treatment NAT nonreactivity as a surrogate for

clinical benefit or as sufficient evidence to support approval. More detailed information about the Company and the risk factors that

may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange

Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30,

2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s

website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s

actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only

as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral,

that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts

Media

Contact:

Kristen Landon

kristenlandon@60degreespharma.com

Investor

Contact:

Patrick Gaynes

patrickgaynes@60degreespharma.com

GRAPHIC

Filename: ea030969001_ex99-1img1.jpg · Sequence: 3

Binary file (6990 bytes)

Download ea030969001_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.3

Cover

Oct. 27, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 27, 2026

Entity File Number

001-41719

Entity Registrant Name

DEGREES PHARMACEUTICALS, INC.

Entity Central Index Key

0001946563

Entity Tax Identification Number

45-2406880

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1025

Connecticut Avenue NW Suite 1000

Entity Address, City or Town

Washington

Entity Address, State or Province

Entity Address, Postal Zip Code

20036

City Area Code

202

Local Phone Number

327-5422

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock, par value $0.0001 per share

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

SXTP

Security Exchange Name

NASDAQ

Warrants, each warrant to purchase one share of Common Stock

Title of 12(b) Security

Warrants,

each warrant to purchase one share of Common Stock

Trading Symbol

SXTPW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=SXTP_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=SXTP_WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: